105 products were found matching "K08844"!

Description: LRRK2 Protein, Human, Recombinant (His) is expressed in E. coli with C-6xHis. The accession number is Q5S007.

A LRRK2 inhibitor (IC50 = 15 nM), selective for LRRK2 over a panel of 44 other kinases but does inhibit MAPK4 and Pim-2 at 1 µM, inhibits FLT3 at 10 µM, decreases the production of Abeta42 in a reporter assay using H4 cells overexpressing Abeta42 (IC50 = 15 µM), inhibits EGF-induced activation of MAPK in...

GSK2578215A is a potent inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 = 8.9 nM) that also inhibits the G2019S mutant of LRRK2 (IC50 = 10.1 nM). It displays selectivity for LRRK2 over a panel of 460 other kinases. GSK2578215A prevents phosphorylation of both wild-type and G2019S LRRK2 in mouse spleen and...

MLi-2 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 = 0.76 nM). It is greater than 100-fold selective for LRRK2 over a panel of 308 protein kinases, as well as a panel of receptors and ion channels, at 10 µM. It increases glucocerebrosidase (GCase) activity in dopaminergic neurons differentiated from...

Leucine-rich repeat kinase 2 (LRRK2) is an enzyme that interacts with parkin, a ligase that is part of the ubiquitin-proteasome system that mediates the targeting of proteins for degradation. Loss of function of the parkin protein leads to dopaminergic cell death. The development of Parkinson's disease has been...

Leucine-rich repeat kinase 2 (LRRK2) is an enzyme that interacts with parkin, a ligase that is part of the ubiquitin-proteasome system that mediates the targeting of proteins for degradation. Loss of function of the parkin protein leads to dopaminergic cell death. The development of Parkinson's disease has been...

Leucine-rich repeat kinase 2 (LRRK2) is an enzyme that interacts with parkin, a ligase that is part of the ubiquitin-proteasome system that mediates the targeting of proteins for degradation. Loss of function of the parkin protein leads to dopaminergic cell death. The development of Parkinson's disease has been...

HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 = 20.3 nM). It also inhibits the G2019S, A2016T, and [G2019S+A2016T] mutants of LRRK2 (IC50s = 3.2, 153, and 95.9 nM, respectively). HG-10-102-01 substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type and G2019S mutant...

JH-II-127 is an orally bioavailable inhibitor of wild-type (WT) and mutant forms of leucine-rich repeat kinase 2 (LRRK2). It inhibits WT LRRK2, as well as LRRK2 containing the G2019S and A2016T substitution mutations (IC50s = 6.6, 2.2, and 47.7 nM, respectively), which are present in certain patients with...

CZC-25146 is a potent inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 = 4.76 nM for the human recombinant kinase). It also inhibits LRRK2G2019S, a mutant linked to neurotoxicity and Parkinson's disease, with an IC50 value of 6.87 nM. CZC-25146 is selective for LRRK2 over a panel of kinases in HeLa cell...

GNE-9065 is an orally bioavailable and potent inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 = 18.7 nM). It is selective for LRRK2 over 178 kinases, inhibiting only TAK1-TAB1 >50% at a concentration of 0.1 µM. GNE-9065 (10 and 50 mg/kg) inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice...

CZC-54252 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50s = 1.28 and 1.85 nM for wild-type and G2019S mutant forms of LRRK2, respectively). It has been shown to protect against neuronal injury induced by Parkinson's disease-related LRRK2-G2019S mutant activity in primary human neurons with an EC50...